VYNE (VYNE Therapeutics) Valuation Rank


VYNE VYNE Therapeutics Inc VYNE
37 GF Score
Price $0.67
GF Value $0.56
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is VYNE Therapeutics Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

VYNE Therapeutics Valuation Rank Related Terms

VYNE
37GF Score
VYNE Therapeutics Inc VYNE
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is VYNE Therapeutics (VYNE) Overvalued in 2026?

Based on GuruFocus' analysis, VYNE Therapeutics stock appears to be overvalued. The current stock price of $0.67 is trading 19.2% above its estimated GF Value™ of $0.56. GuruFocus considers VYNE Therapeutics to be Modestly Overvalued.

Key valuation signals for VYNE:

  • Valuation Rank:
  • GF Value™: $0.56 vs. price of $0.67 (19.2% above fair value)
  • GF Score™: 37/100 with 5 warning signs

No single metric tells the full story. See the VYNE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

VYNE Therapeutics Business Description

Address P.O. Box 125, Stewartsville, NJ, USA, 08886
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
37GF Score

Get the complete analysis for VYNE

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.67
Price
$0.56
GF Value